Weiß, C., Ziegler, A., Becker, L., Johannsen, J., Brennenstuhl, H., Schreiber, G., . . . Kaindl, A. M. (2022). Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: An observational cohort study. The lancet child & adolescent health, 6(1), . https://doi.org/10.1016/S2352-4642(21)00287-X
Chicago-Zitierstil (17. Ausg.)Weiß, Claudia, et al. "Gene Replacement Therapy with Onasemnogene Abeparvovec in Children with Spinal Muscular Atrophy Aged 24 Months or Younger and Bodyweight Up to 15 Kg: An Observational Cohort Study." The Lancet Child & Adolescent Health 6, no. 1 (2022). https://doi.org/10.1016/S2352-4642(21)00287-X.
MLA-Zitierstil (9. Ausg.)Weiß, Claudia, et al. "Gene Replacement Therapy with Onasemnogene Abeparvovec in Children with Spinal Muscular Atrophy Aged 24 Months or Younger and Bodyweight Up to 15 Kg: An Observational Cohort Study." The Lancet Child & Adolescent Health, vol. 6, no. 1, 2022, https://doi.org/10.1016/S2352-4642(21)00287-X.